Evidence map›Paper›PMID 32947094›Full record

ArticleBiomaterials2020

Enhanced stem cell retention and antioxidative protection with injectable, ROS-degradable PEG hydrogels.

John R Martin, Prarthana Patil, Fang Yu, Mukesh K Gupta, Craig L Duvall

Abstract read
In one paragraph

Article in Biomaterials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Hybrid Hydrogels in Pain Management Application: A Comprehensive Review.Clinical pharmacology : advances and applications · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. Delivering living medicines with biomaterials.Nature reviews. Materials · 2025
    Article
  11. Article
  12. Biomaterial-Based Therapeutic Delivery of Immune Cells.Advanced healthcare materials · 2025
    Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

John R MartinBiomedical Engineering, Vanderbilt University, 5824 Stevenson Center, PMB 351631, Nashville, TN, 37235-1631, USA.
Prarthana PatilBiomedical Engineering, Vanderbilt University, 5824 Stevenson Center, PMB 351631, Nashville, TN, 37235-1631, USA.
Fang YuBiomedical Engineering, Vanderbilt University, 5824 Stevenson Center, PMB 351631, Nashville, TN, 37235-1631, USA.
Mukesh K GuptaBiomedical Engineering, Vanderbilt University, 5824 Stevenson Center, PMB 351631, Nashville, TN, 37235-1631, USA. Electronic address: mukesh.k.gupta@vanderbilt.edu.
Craig L DuvallBiomedical Engineering, Vanderbilt University, 5824 Stevenson Center, PMB 351631, Nashville, TN, 37235-1631, USA. Electronic address: craig.duvall@vanderbilt.edu.

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8M
Vanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9M
Substrate Mediated siRNA Delivery from Scaffolds to Promote Wound RepairR01EB019409 · NIBIB · VANDERBILT UNIVERSITY · PI Craig Lewis Duvall · 2014 to 2026
$4.0M
Integrated Training in Engineering and DiabetesT32DK101003 · NIDDK · VANDERBILT UNIVERSITY · PI Jamey D. Young · 2014 to 2026
$3.9M
Hybrid Synthetic and Biologic Shear Thinning Hydrogels for Diabetic Wound HealingR01EB028690 · NIBIB · VANDERBILT UNIVERSITY · PI DUVALL, CRAIG LEWIS, GUPTA, MUKESH KUMAR · 2019 to 2023
$2.0M
NCI NIH HHS P30 CA068485NIBIB NIH HHS R01 EB019409NIBIB NIH HHS R01 EB028690NIDDK NIH HHS T32 DK101003NIDDK NIH HHS U24 DK059637
6 · The paper itself

Abstract

Poly(ethylene glycol) (PEG) hydrogels crosslinked with enzyme-cleavable peptides are promising biodegradable vehicles for therapeutic cell delivery. However, peptide synthesis at the level required for bulk biomaterial manufacturing is costly, and fabrication of hydrogels from scalable, low-cost synthetic precursors while supporting cell-specific degradation remains a challenge. Reactive oxygen species (ROS) are cell-generated signaling molecules that can also be used as a trigger to mediate specific in vivo degradation of biomaterials. Here, PEG-based hydrogels crosslinked with ROS-degradable poly(thioketal) (PTK) polymers were successfully synthesized via thiol-maleimide chemistry and employed as a cell-degradable, antioxidative stem cell delivery platform. PTK hydrogels were mechanically robust and underwent ROS-mediated, dose-dependent degradation in vitro, while promoting robust cellular infiltration, tissue regeneration, and bioresorption in vivo. Moreover, these ROS-sensitive materials successfully encapsulated mesenchymal stem cells (MSCs) and maintained over 40% more viable cells than gold-standard hydrogels crosslinked with enzymatically-degradable peptides. The higher cellular survival in PTK-based gels was associated with the antioxidative function of the ROS-sensitive crosslinker, which scavenged free radicals and protected encapsulated MSCs from cytotoxic doses of ROS. Improved MSC viability was also observed in vivo as MSCs delivered within injectable PTK hydrogels maintained significantly more viability over 11 days compared against cells delivered within gels crosslinked with either a PEG-only control polymer or a gold-standard enzymatically-degradable peptide. Together, this study establishes a new paradigm for scalable creation and application of cell-degradable hydrogels, particularly for cell delivery applications.

Indexed as

Biocompatible MaterialsMesenchymal Stem CellsAntioxidantsHydrogelsPolyethylene GlycolsReactive Oxygen SpeciesAntioxidantsBiocompatible MaterialsHydrogelsPolyethylene GlycolsReactive Oxygen SpeciesBiodegradationHydrogelInjectable materialReactive oxygen speciesStem cell

Identifiers

PMID32947094
PMCPMC8112229

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.